The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

Scientists have identified a promising new class of treatments for Alzheimer's disease, and they're already widely used to treat HIV and hepatitis B. Along with their antiretroviral effects, drugs ...